July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
FGF21 restores photoreceptor function in type 1 diabetic mice
Author Affiliations & Notes
  • Ricky Cui
    School of Medicine, Mayo Clinic, Rochester, Minnesota, United States
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Zhongjie Fu
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Zhongxiao Wang
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Chi-Hsiu Liu
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Yan Gong
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Bertan Cakir
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Raffael Liegl
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Ye Sun
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Rubi Duran
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Alexander Poblete
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Steve S Cho
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Saswata Talukdar
    Merck Research Laboratories, Boston, Massachusetts, United States
  • James D Akula
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Ann Hellstrom
    Section for Ophthalmology, Department of Clinical Neuroscience and rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
  • Lois E. H. Smith
    Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Ricky Cui, None; Zhongjie Fu, None; Zhongxiao Wang, None; Chi-Hsiu Liu, None; Yan Gong, None; Bertan Cakir, None; Raffael Liegl, None; Ye Sun, None; Rubi Duran, None; Alexander Poblete, None; Steve Cho, None; Saswata Talukdar, None; James Akula, None; Ann Hellstrom, None; Lois Smith, None
  • Footnotes
    Support  NIH EY024864, EY017017, BCH IDDRC (1U54HD090255), Lowy Medical Research Institute, European Commission FP7 project 305485 PREVENT-ROP (LEHS); The Swedish Research Council (DNR# 2011-2432), Gothenburg County Council (ALFGBG-426531) long-term support by De Blindas Vänner and Kronprinsessan Margaretas Arbetsnämnd för synskadade, and European Commission FP7 project 305485 (AH); ZF is supported by Knights Templar Eye Foundation (#76293) and Blind Children's Center (#89282); the German Research Foundation (DFG), Li2650/1-1 (RL). Knights Templar Eye Foundation (CHL); Boston Children's Hospital OFD/BTREC/CTREC Faculty Career Development Grant (YS); Deutsche Forschungsgemeinschaft (DFG) (B.C.)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3570. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ricky Cui, Zhongjie Fu, Zhongxiao Wang, Chi-Hsiu Liu, Yan Gong, Bertan Cakir, Raffael Liegl, Ye Sun, Rubi Duran, Alexander Poblete, Steve S Cho, Saswata Talukdar, James D Akula, Ann Hellstrom, Lois E. H. Smith; FGF21 restores photoreceptor function in type 1 diabetic mice. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3570.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic retinopathy (DR) is a common complication in diabetes with vision-threatening neovascularization. Retinal neuronal changes occur before vascular changes in DR. Accumulating experimental evidence suggests that neurons control vascular pathology in neovascular retinal diseases. Therefore, normalizing retinal neuronal activity may prevent vascular pathology. Fibroblast growth factor 21 (FGF21) regulates lipid metabolism in obese patients, non-human primates and mice. We have reported that FGF21 inhibits hypoxia-induced retinal neovascularization in mice, but its impact on retinal neurons is unknown. The purpose of this study is to investigate the impact of FGF21 on retinal function at early DR.

Methods : In diabetic male mice (Akita or streptozotocin-induced), we examined the retinal neuronal activity before and after the long-acting FGF21 analog, PF-05231023 administration by electroretinography (n=5-10), photoreceptor structure with immunohistochemistry (rhodopsin for rods and cone arrestin for cones), as well as retinal thickness by optical coherence tomography (OCT, n=4-10). Retinal and photoreceptor (661W cells) inflammation was examined by Western Blot and qPCR (n=3-4). Correlation of post-receptor cell sensitivity with the sum of changes in photoreceptor in Akita mice was assessed by Pearson r test (n=10). T-test or ANOVA was used for statistical analysis.

Results : In diabetic neural retina, photoreceptor rather than inner retinal function was most affected (post-receptor vs photoreceptor changes: P=0.01). PF-05231023 administration protected against diabetes-induced decrease in retinal sensitivity (Akita vs WT: P=0.00046; PF-05231023- vs vehicle-treated Akita: P=0.00001). PF-05231023 restored disorganization of cone structure seen in retinal cross section and the reduction in the thickness of photoreceptor segments measured by OCT. PF-05231023 reduced pro-inflammatory IL-1β gene expression in diabetic retinas (Akita vs WT: P=0.0483; PF-05231023- vs vehicle-treated Akita: P=0.0036). PF-05231023 activated the AKT pathway and normalized NRF2 levels in diabetic retinas. PF-05231023 administration did not change retinal expression of Vegfa.

Conclusions : Our findings suggest that FGF21 may be a novel therapeutic potential for the prevention of early DR.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×